

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

CHANGE OF TRUSTEE OF THE 2018 SHARE AWARD SCHEME

Reference is made to the announcement of CSPC Pharmaceutical Group Limited (the “**Company**”) dated 20 August 2018 in relation to the adoption of the restricted share award scheme (the “**2018 Share Award Scheme**”) of the Company (the “**Announcement**”), the terms of which were subsequently amended as disclosed in the voluntary announcement of the Company dated 21 May 2024. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board announces that the change of the trustee of the 2018 Share Award Scheme (the “**Trustee**”) in accordance with the Scheme Rules shall take effect from 12 August 2026. The Company shall engage BOCI Trustee (Hong Kong) Limited (“**BOCI Trustee**”) as the Trustee in replacement of BOCI-Prudential Trustee Limited (“**BOCI-Prudential**”), and an amended and restated trust deed shall be executed between the Company and BOCI Trustee to give effect to such change.

BOCI-Prudential confirmed that it has no disagreement with the Company, and there is no matter relating to the change of Trustee that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The change of the Trustee will not affect the subsisting rights of the Selected Participants under the 2018 Share Award Scheme. Save for the change of the Trustee, all other terms in the Scheme Rules remain unchanged.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 12 August 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.